Colonoscopy Screening for Ulcerative Colitis: Cost-Effectiveness

By Staff Writer

March 18, 2024

Introduction

Ulcerative colitis (UC), a chronic disease impacting the large intestine. It is becoming increasingly prevalent, not just globally, but also specifically in Saudi Arabia. Individuals with long-standing UC are at a higher risk of developing colorectal cancer (CRC), a serious complication associated with inflammatory bowel disease (IBD). With the potential risk of CRC in UC patients being 1.7 times higher than the general population, it is crucial to establish effective and cost-effective screening methods.

The Controversy Surrounding Surveillance Colonoscopy

Surveillance colonoscopy, a method used to detect dysplasia in UC patients, has been shown to be effective in reducing CRC rates. Yet, there is ongoing debate about the cost-effectiveness of this screening method. While some studies suggest that surveillance can increase life expectancy, others argue that it may not always be cost-effective. Especially in the Middle Eastern context, this is observed.

The Saudi Scenario

A recent study focused on the cost-consequence analysis of annual colonoscopy surveillance among high-risk UC patients in Saudi Arabia. The findings revealed that this practice results in higher costs but lower rates of dysplasia detection. They found that each 1% reduction in dysplasia rates was associated with an incremental cost of USD 740.125. If we assume that a 50% decrease in high grade dysplasia rates will lead to at least one extra quality-adjusted life year (QALY), then the USD 37,006.25 (50 times USD 740.125) is more than the recently released cost-effectiveness threshold for Saudi Arabia, which is USD 20,183 per QALY.

Limitations of Annual Screening

The cost-effectiveness of annual colonoscopy screening among high-risk UC patients in the Middle Eastern population is yet to be reported. A systematic review found that all CRC screening techniques were more cost-effective than no screening at different cost-effectiveness criteria. Although a colonoscopy every 10 years was cost-effective, most trials reported greater costs than no screening, and ICERs exceeded USD 20,000 in several cases. Furthermore, the discomfort associated with colonoscopy and the lack of endoscopic capacity in Saudi Arabia make annual colonoscopy screening not just cost-ineffective but inconvenient to patients and the healthcare system.

Potential AI Intervention

The potential of artificial intelligence (AI) in screening CRC is worth investigating. A study examining the adoption of AI in colonoscopy for CRC screening resulted in a significant reduction in CRC incidence (8.4 %) and mortality (6.9 %), suggesting a promising direction for future research.

The Role of Albumin Levels

The study also revealed that patients who had higher albumin levels were less likely to have dysplasia compared to those with hypoalbuminemia. This finding is consistent with another study that examined the use of albumin as a prognostic marker for ulcerative colitis.

Concluding Thoughts

Adherence to annual colonoscopy for CRC screening has resulted in higher rates of dysplasia detection among long-standing UC patients. However, this comes with a significant incremental cost. Based on recent findings, performing colonoscopy for CRC screening on an annual basis is likely to be inefficient. Thus, longitudinal prospective cohort studies should examine the cost-effectiveness of various CRC screening strategies, including 5-year and 10-year colonoscopies.

Reference url

Recent Posts

suzetrigine pain management
      

Journavx for Pain Management: Toward Affordability and Access

💊 The jury is out on the pricing for Journavx®

Delve into our review of the recent ICER 2025 report on suzetrigine (Journavx®) to learn about the anticipated value relative to its clinical efficacy, safety profile and potential cost savings in tackling acute pain while addressing the opioid crisis.

Explore how suzetrigine paves the way for a safer, more effective approach to pain management and its implications on healthcare economics.

#SyenzaNews #HealthEconomics #HealthcareInnovation #Journavx

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.